Trial Profile
Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tomuzotuximab (Primary) ; Cetuximab; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RESGEX
- Sponsors Glycotope
- 20 Oct 2020 Status changed from active, no longer recruiting to completed.
- 28 Oct 2017 This study has been Discontinued in Spain
- 13 Oct 2017 Trail has been Discontinued in Poland.